Alphabet's AI Drug Lab Just Raised More Than Most Biotechs Are Worth

The company claims IsoDDE can find these binding sites from nothing more than an amino acid sequence. No crystal structure needed. No months of lab work to figure out what the target looks like. Just the genetic code and a lot of math.

Show Me the Drugs

This is where skeptics sharpen their pencils. Isomorphic has no drugs in human trials yet. Zero clinical data. The pipeline sits in preclinical stages across oncology, immunology, and cardiovascular disease, with the company targeting first-in-human trials by end of 2026.

But the pharma partnerships suggest the science isn't just theoretical. Eli Lilly signed a deal in January 2024 worth up to $1.7 billion in milestones (plus royalties), with $45 million upfront. Novartis inked a similar agreement worth up to $1.2 billion, covering three undisclosed targets. Johnson & Johnson joined later with a cross-modality collaboration spanning small molecules, biologics, peptides, and molecular glues.

Three of the world's largest drug companies paying real money for AI-designed molecules: that's validation you can't fake with a press release.

The "Solve All Disease" Ambition

Demis Hassabis, the company's founder and CEO (who also runs DeepMind and won the 2024 Nobel Prize in Chemistry for AlphaFold), didn't mince words. "This funding round is a massive vote of confidence," he said. "Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential, driving us forward in our mission to solve all disease."

"Solve all disease" is either the most ambitious mission statement in biotech or the most delusional. Probably both. But with $2.7 billion in the bank, a Nobel laureate at the helm, and partnerships with Lilly, Novartis, and J&J already generating revenue, Hassabis has more credibility than most people making that claim.

What This Means for AI-Biotech

The round lands at an interesting moment. AI drug discovery has been promising "better, faster, cheaper" for years, and some cracks have appeared. The merged Recursion-Exscientia entity is still searching for breakout clinical wins. Insilico Medicine's lead candidate showed encouraging Phase 2a results, but "encouraging" is a long way from "approved."

Isomorphic's massive war chest lets it play a different game entirely. While competitors raise $100 million here and $150 million there, Isomorphic can afford to run dozens of programs simultaneously, hire aggressively across London, Cambridge (MA), and Lausanne, and absorb failures without existential risk.

As FierceBiotech put it: "If any proof was needed that big money is still available for AI drug development, look no further."

The Big Question Nobody Can Answer Yet

All of this only matters if AI-designed drugs actually work in humans. Proteins folding on a computer screen is elegant. Patients getting better is something else entirely. The gap between computational prediction and clinical reality has humbled smarter companies than this one.

But if Isomorphic's first clinical candidates succeed (expected to enter trials by late 2026), the implications are staggering. A validated AI drug design engine could compress years of discovery into months, dramatically reduce the cost of bringing a drug to market, and open up targets that traditional chemistry couldn't crack.

For now, $2.1 billion buys Isomorphic something invaluable: time to prove the thesis before anyone else does. The clock is ticking, the money is in the bank, and the entire industry is watching.

Pfizer Just Crashed the Hardest Party in Hemophilia

Pfizer just won EU approval to treat the hardest cases in hemophilia: patients whose immune systems attack their own medication. The Phase 3 data showed a 93% drop in bleeding, and the competitive implications are fascinating.